References
- Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15. https://doi.org/10.1186/cc8872
- Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev 2012;25:609-634. https://doi.org/10.1128/CMR.00016-12
- Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-518. https://doi.org/10.1016/0140-6736(93)90277-N
- Huang HB, Peng JM, Weng L, Wang CY, Jiang W, Du B. Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis. Ann Intensive Care 2017;7:114. https://doi.org/10.1186/s13613-017-0338-6
- Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-e111. https://doi.org/10.1093/cid/ciw353
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304-377. https://doi.org/10.1007/s00134-017-4683-6
- Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048-2058. https://doi.org/10.1097/CCM.0b013e31821e8791
- Layios N, Lambermont B, Canivet JL, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 2012;40:2304-2309. https://doi.org/10.1097/CCM.0b013e318251517a
- Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-474. https://doi.org/10.1016/S0140-6736(09)61879-1
- Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld AB. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect 2015;21:474-481. https://doi.org/10.1016/j.cmi.2014.12.026
- Yan ST, Sun LC, Jia HB, Gao W, Yang JP, Zhang GQ. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. Am J Emerg Med 2017;35:579-583. https://doi.org/10.1016/j.ajem.2016.12.017
- Nakamura Y, Murai A, Mizunuma M, et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury. J Infect Chemother 2015;21:257-263. https://doi.org/10.1016/j.jiac.2014.12.001
- Oussalah A, Ferrand J, Filhine-Tresarrieu P, et al. Diagnostic accuracy of procalcitonin for predicting blood culture results in patients with suspected bloodstream infection: an observational study of 35,343 consecutive patients (a STROBE-compliant article). Medicine (Baltimore) 2015;94:e1774. https://doi.org/10.1097/MD.0000000000001774
- Cha JK, Kwon KH, Byun SJ, et al. Clinical value of procalcitonin for suspected nosocomial bloodstream infection. Korean J Intern Med 2018;33:176-184. https://doi.org/10.3904/kjim.2016.119
- Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007;50:34-41. https://doi.org/10.1016/j.annemergmed.2006.10.020
- Contou D, d'Ythurbide G, Messika J, et al. Description and predictive factors of infection in patients with chronic kidney disease admitted to the critical care unit. J Infect 2014;68:105-115. https://doi.org/10.1016/j.jinf.2013.10.003
- Lee WS, Kang DW, Back JH, Kim HL, Chung JH, Shin BC. Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients. Korean J Intern Med 2015;30:198-204. https://doi.org/10.3904/kjim.2015.30.2.198
Cited by
- Epidemiology of bloodstream infection in Saudi Arabia vol.12, pp.43, 2018, https://doi.org/10.5897/ajmr2018.8988